HK-013

N/A

Report date: 2022/05/27 12:20:06

Base Information

Drug NameHK-013

Drug Alias NameHK-013

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-MesothelinTumor necrosis factor receptor superfamily member 9 agonists

TargetsMesothelinTumor necrosis factor receptor superfamily member 9

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesHefei Hankemab Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesHefei Hankemab Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A